HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

AbstractPURPOSE:
To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-D-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent with the potential to target the glucose transporter system.
PATIENTS AND METHODS:
Twenty-one patients (10 women and 11 men; median age, 56 years) with refractory solid tumors were treated with doses ranging from 800 to 6,000 mg/m(2). Glufosfamide was administered every 3 weeks as a two-step (fast/slow) intravenous infusion over a 6-hour period. All patients underwent pharmacokinetic sampling at the first course.
RESULTS:
The MTD was 6,000 mg/m(2). At this dose, two of six patients developed a reversible, dose-limiting renal tubular acidosis and a slight increase in serum creatinine the week after the second and third courses of treatment, respectively, whereas three of six patients experienced short-lived grade 4 neutropenia/leukopenia. Other side effects were generally mild. Pharmacokinetics indicated linearity of area under the time-versus-concentration curve against dose over the dose range studied and a short elimination half-life. There was clear evidence of antitumor activity, with a long-lasting complete response of an advanced pancreatic adenocarcinoma and minor tumor shrinkage of two refractory colon carcinomas and one heavily pretreated breast cancer.
CONCLUSION:
The principal toxicity of 6-hour infusion of glufosfamide is reversible renal tubular acidosis, the MTD is 6,000 mg/m(2), and the recommended phase II dose is 4, 500 mg/m(2). Close monitoring of serum potassium and creatinine levels is suggested for patients receiving glufosfamide for early detection of possible renal toxicity. Evidence of antitumor activity in resistant carcinomas warrants further clinical exploration of glufosfamide in phase II studies.
AuthorsE Briasoulis, I Judson, N Pavlidis, P Beale, J Wanders, Y Groot, G Veerman, M Schuessler, G Niebch, K Siamopoulos, E Tzamakou, D Rammou, L Wolf, R Walker, A Hanauske
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 18 Issue 20 Pg. 3535-44 (Oct 15 2000) ISSN: 0732-183X [Print] United States
PMID11032596 (Publication Type: Case Reports, Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Monosaccharide Transport Proteins
  • Phosphoramide Mustards
  • beta-D-glucosylisophosphoramide mustard
  • Glucose
  • Ifosfamide
Topics
  • Adult
  • Aged
  • Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, pharmacokinetics)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Glucose (analogs & derivatives)
  • Humans
  • Ifosfamide (analogs & derivatives)
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Monosaccharide Transport Proteins (biosynthesis, metabolism)
  • Neoplasms (drug therapy, metabolism)
  • Phosphoramide Mustards (administration & dosage, adverse effects, pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: